Celgene (CELG) Upgraded at BidaskClub

BidaskClub upgraded shares of Celgene (NASDAQ:CELG) from a sell rating to a hold rating in a research report released on Tuesday.

Other analysts have also issued reports about the stock. Cantor Fitzgerald restated a buy rating and set a $162.00 price objective on shares of Celgene in a research note on Tuesday, September 26th. Robert W. Baird restated a buy rating and set a $162.00 price objective on shares of Celgene in a research note on Thursday, September 21st. Jefferies Group restated a buy rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. Mizuho raised their price objective on shares of Celgene from $134.00 to $158.00 and gave the company a buy rating in a research note on Friday, September 15th. Finally, Vetr lowered shares of Celgene from a strong-buy rating to a buy rating and set a $146.88 price objective for the company. in a research note on Tuesday, August 29th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Celgene currently has an average rating of Buy and an average price target of $136.21.

Celgene (NASDAQ:CELG) traded up $1.17 during trading hours on Tuesday, reaching $109.41. 9,719,225 shares of the company’s stock were exchanged, compared to its average volume of 5,339,085. The company has a market cap of $85,219.19, a price-to-earnings ratio of 16.91, a P/E/G ratio of 0.83 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 1-year low of $94.55 and a 1-year high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $1.58 EPS. sell-side analysts anticipate that Celgene will post 6.68 EPS for the current fiscal year.

In related news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.95% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. lifted its holdings in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI lifted its holdings in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares in the last quarter. Robecosam AG purchased a new position in Celgene during the third quarter valued at approximately $114,000. Guidant Wealth Advisors purchased a new position in Celgene during the third quarter valued at approximately $119,000. Finally, Capital Bank & Trust Co lifted its holdings in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 517 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Celgene (CELG) Upgraded at BidaskClub” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/12/16/celgene-celg-upgraded-at-bidaskclub.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply